Previously, we revealed that AM095, an LPAR1 inhibitor, can ameliorate DN by suppressing TLR4/NF-κB signaling-mediated inflammation in the mesangial cells of STZ-induced diabetic mice [13]. This evidence concerns the gene NFKB1 and liver dysplastic nodule.